Teva shares topple on profit warning, uncertain future


By Steven Scheer and Ari Rabinovitch JERUSALEM (Reuters) – Teva Pharmaceutical Industries , the world’s biggest generic medicine maker, came under investor and market pressure on Thursday after saying it would miss 2017 profit forecasts. Shares in the Israeli-based company dropped by as much as 20 percent after it issued the profit warning, which it said was due to falling prices of generics in the U.S. market and weakening sales of its multiple sclerosis drug Copaxone, which fell 7 percent in the third quarter in the United States. Investors are pushing Teva, which is battling narrowing profit margins, a nearly $35 billion debt burden that could lead to a credit rating downgrade, for clarity on its future.

Комментариев нет

Добавить комментарий

Этот сайт использует Akismet для борьбы со спамом. Узнайте как обрабатываются ваши данные комментариев.

Michigan Woman Thought She Won $500 Lotto Prize, Later Learns It Was $1 Million

It took her two days to realize she won the top prize.

The “$35,000 Tesla Model 3” Still Doesn't Exist

And it won't until at least the end of 2018.

Historic non-stop flight between Australia and UK takes off

Passengers have taken off for the first direct flight between Australia and London, passing a major milestone by reducing to 17 hours a trip that once took 12 1/2 days. The 9,000-mile flight from Perth, one of the world’s most isolated cities, marks the first direct passenger service between the continents. …